EU approves AbbVie's Skyrizi for children with plaque psoriasis
Go back to EU approves AbbVie's Skyrizi for children with plaque psoriasis| AbbVie (NYSE: ABBV) | Delayed: 256.23 +2.93 (1.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $253.30 | 52 Week High | $68.12 | |||
| Open | $253.98 | 52 Week Low | $50.71 | |||
| Day High | $258.38 | P/E | 55.58 | |||
| Day Low | $253.10 | EPS | $4.61 | |||
| Volume | 2,335,935 | |||||
